You are leaving our website

You have clicked on a link that will take you to a third-party website that Alliance Pharmaceuticals plc group (“Alliance”) is not responsible for.

Please read the following disclaimer and click “I agree” to proceed to the third-party website.

By clicking to continue you agree that:You are leaving Alliance`s website.

Alliance:

  • Is not responsible for the content or accuracy of the third-party website nor endorse or guarantee any services or information they may offer.
  • Does not represent either the third-party website or you (the visitor) if you enter into an agreement or transaction.
  • Privacy and security policies do not apply to third-party websites.
or Decline

Appointment of Finance Director

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to announce the appointment of Andrew Franklin as Finance Director. Andrew will join the Company and the Board with effect from 28 September 2015.

From 2010 to 2012, Andrew was finance director and company secretary of Genzyme Therapeutics Ltd, the UK & Ireland subsidiary of Genzyme Corporation, the biotechnology company acquired by Sanofi. Prior to that, he gained 12 years' pharmaceutical experience with Wyeth in a variety of senior financial positions. Andrew joins Alliance from Panasonic Europe Ltd, where he was general manager, European tax and accounting.

He qualified as a chartered accountant with Arthur Andersen in 1992 having graduated in 1988 with a first class degree in civil engineering from University of Wales, Cardiff.

“We welcome Andrew to Alliance as our new Finance Director. He brings considerable experience, having operated for 14 years in senior financial roles in the pharmaceutical industry. Andrew will be a strong addition to the Alliance team.”

John Dawson,Chief Executive Officer of Alliance

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Andrew Timothy Franklin, aged 49 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships

None

Past directorships

Genzyme Therapeutics Limited

Bioenvision Limited

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

For further information:

Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer

Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black

Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.